Genetically determined Alzheimer's disease research advances: The Down Syndrome & Autosomal Dominant Alzheimer's Disease 2024 Conference
作者：Neus Falgàs, Lucía Maure-Blesa, Beau M. Ances, Lisi Flores Aguilar, Sigan L. Hartley, Jason Hassenstab, M. Florencia Iulita, Matthew P. Janicki, Katherine Koenig, Patrick J. Lao, Johannes Levin, Eric McDade, Laurent Meijer, Michael S. Rafii, Heather M. Snyder, Raquel Sánchez‐Valle, Juan Fortea, DSAD‐ADAD conference group, Jon Infante, Mircea Balasa, Isabel Barroeta, Nithish Gowtham A R -, Alexandre Bejanin, Bessy Benejam, Beatríz Bosch, Angela C. Bradshaw, María Carmona‐Iragui, Ann D. Cohen, Aina Comas Albertí, Lajos Csincsik, A. Claudio Cuello, Laura del Hoyo Soriano, Janna I.R. Dijkstra, Natalie C. Edwards, Sandra Giménez, Fernando González‐Ortiz, Brian A. Gordon, Sara Gutiérrez Fernández, Benjamin L. Handen, Charlotte Jacob, Erik C. B. Johnson, Charlotte Johansson, Albert Lladó, Alberto Lleó, Samuel Morabito, Alejandra O. Morcillo‐Nieto, Laia Montoliu‐Gaya, Michael Okafor, Agnès Pérez‐Millan, Marie Claude Potier, John M. Ringman, Íñigo Rodríguez‐Baz, Eric Rubenstein, Natalie S. Ryan, André Strydom, Lídia Vaqué‐Alcázar, Lisa Vermunt, Laura Videla Toro, Shahid Zaman · 发表于：Alzheimer s & Dementia · 年份：2025 · DOI：10.1002/alz.70309 · 被引用次数：5 · 研究领域：Down syndrome and intellectual disability research、Genomics and Rare Diseases、Genetic Neurodegenerative Diseases
INTRODUCTION: The Down syndrome-associated Alzheimer's disease (DSAD) autosomal dominant Alzheimer's disease (ADAD) 2024 Conference in Barcelona, convened under an Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) grant through the Down syndrome and Alzheimer's disease (AD) Professional Interest Area (PIA), brought together global researchers to foster collaboration and knowledge exchange between the fields of DSAD and ADAD. METHODS: This article provides a synthesis review of the conference proceedings, summarizing key discussions on biomarkers, natural history models, clinical trials, and ethical considerations in anti-amyloid therapies. RESULTS: A total of 211 attendees from 16 countries joined the meeting. Global researchers presented on disease mechanisms, therapeutic developments, and patient care strategies. Discussions focused on challenges and opportunities unique to DSAD and ADAD. Experts emphasized the urgent need for tailored clinical trials for ADAD and DSAD and debated the safety and efficacy of anti-amyloid treatments. Ethical considerations highlighted equitable access to therapies and the crucial role of patient and caregiver involvement. DISCUSSION: The conference highlighted the importance of inclusive research and collaboration across the genetic forms of AD. HIGHLIGHTS: Biomarker research and natural history models developed in Down syndrome-associated Alzheimer's disease (DSAD) and autosomal dominant Al...